Compare Equinor ASA (EQNR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs Recursion Pharmaceuticals Inc — how do they compare? Equinor ASA trades at $43 (market cap $101.62B), while Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B). The key difference: Equinor ASA is far larger — about 47.5× Recursion Pharmaceuticals Inc's market cap, and Equinor ASA pays a 3.63% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinor ASA for 59 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| EQNR | RXRX | |
|---|---|---|
Market Cap | $101.62B | $2.14B |
Volume | 4,991,782 | 30,789,535 |
Sector | Energy | Health |
52-Week High | $45.75 | $6.79 |
52-Week Low | $22.41 | $2.84 |
Typical Hold Time | 59 Days | 22 Days |
Enterprise Value | $110.31B | $1.66B |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinor (EQNR) trades at $41.61, down 3.26% today, with a bearish technical signal despite strong valuation metrics including a P/E of 11.28 and EV/EBITDA of 2.35. The company has beaten earnings estimates in two of the last three quarters, with Q3 2026 results pending. Recent news highlights expansion in LNG and carbon capture projects, while cash flow trends show improving operational performance from 2025 levels.
EQNR presents a compelling value opportunity with significant upside to the $70.50 consensus price target, though near-term technical weakness and declining profit margins from 2022 peaks pose risks. The stock's 21.32% ROE and dividend payments support income investors, while LNG expansion plans provide growth catalysts. Market sentiment remains mixed with 30% buy ratings amid energy sector volatility.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
